7
Participants
Start Date
July 29, 2022
Primary Completion Date
December 31, 2023
Study Completion Date
May 31, 2024
TQB3602 Capsule + AK105 Injection
TQB3602 is a kind of proteasome inhibitor, AK105 is an anti-PD-1 antibody.
Nong Yang, Changsha
Sun Yat-sen University Cancer Center, Guangzhou
Lead Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
INDUSTRY